NYSE: $MRK
RAHWAY, N.J.–(BUSINESS WIRE) November 9, 2026 — Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of positive results from the company’s Phase 2b clinical trial that evaluated the…
Source: Read More